Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series

Immune checkpoint inhibitor-related colitis is a common complication of immunotherapy use in patients with cancer. Current guidelines recommend treatment with standard dose infliximab (IFX) for corticosteroid-refractory colitis; however, this case series suggests IFX dose escalation may be a viable...

Descripción completa

Detalles Bibliográficos
Autores principales: Harris, Jessica P, Postow, Michael A, Faleck, David M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982418/
https://www.ncbi.nlm.nih.gov/pubmed/35380715
http://dx.doi.org/10.1093/oncolo/oyac019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982418/
https://www.ncbi.nlm.nih.gov/pubmed/35380715
http://dx.doi.org/10.1093/oncolo/oyac019

Ejemplares similares